Research ArticleEfficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials
Under a Creative Commons license
open access
Abbreviations
HCV
hepatitis C virus
GT
genotype
TPV
telaprevir
PegIFN
pegylated interferon
RBV
ribavirin
SVR
sustained virologic response
DAA
direct-acting antiviral agents
OBV
ombitasvir
PTV
paritaprevir
r
ritonavir
DSV
dasabuvir
IL28B
interleukin 28B
RNA
ribonucleic acid
MEMS
Medication Event Monitoring System
PCR
polymerase chain reaction
LLOQ
lower limit of quantitation
SF-36v2
Short Form–36 version 2 Health Survey
PRO
patient-reported outcome
MCS
mental component summary
PCS
physical component summary
WPAI-HCV
work productivity and impairment questionnaire specific for HCV
ANCOVA
analysis of covariance
CI
confidence interval
OATP
organic anion-transporting polypeptide
Keywords
Hepatitis C virus
Telaprevir
Interferon-free therapy
Direct-acting antivirals
Sustained virologic response
Cited by (0)
- †
These authors contributed equally to this work.
Copyright © 2015 The Authors. Published by Elsevier B.V.